Show simple item record

dc.contributor.authorVangavaragu, Jhansi Rani
dc.contributor.authorValasani, Koteswara Rao
dc.contributor.authorDu, Fang
dc.contributor.authorWilliams, Todd D.
dc.contributor.authorYan, Shirley ShiDu
dc.date.accessioned2017-04-03T21:32:06Z
dc.date.available2017-04-03T21:32:06Z
dc.date.issued2014-04-02
dc.identifier.citationVangavaragu, Jhansi Rani, Koteswara Rao Valasani, Du Fang, Todd D. Williams, and Shirley ShiDu Yan. "Determination of Small Molecule ABAD Inhibitors Crossing Blood Brain Barrier and Pharmacokinetics." Journal of Alzheimer's Disease 42 (2014): 333-44.en_US
dc.identifier.urihttp://hdl.handle.net/1808/23570
dc.description.abstractA major obstacle to the development of effective treatment of Alzheimer’s disease (AD) is successfully delivery of drugs to the brain. We have previously identified a series of benzothiazole phosphonate compounds that block the interaction of amyloid beta peptide (Aβ) with amyloid-beta binding alcohol dehydrogenase (ABAD). A selective and sensitive method for the presence of three new benzothiazole ABAD inhibitors in mouse plasma, brain and artificial cerebrospinal fluid has been developed and validated based on high performance liquid chromatography tandem mass spectrometry. Mass spectra were generated using Micromass Quattro Ultima “triple” quadrupole mass spectrometer equipped with Electrospray ionization interface. Good linearity was obtained over a concentration range of 0.05–2.5 µg/ml. The lowest limit of quantification and detection was 0.05µg/ml. All inter-day accuracies and precisions were within ±15% of the nominal value and ±20%, respectively, at the lower limit of quantitation. The tested compounds were stable at various conditions with recoveries >90.0 % (RSD<10%). The method used for pharmacokinetic studies of compounds in mouse cerebrospinal fluid, plasma, and brain is accurate, precise, and specific with no matrix effect. Pharmacokinetic data showed these compounds penetrate the blood–brain barrier (BBB) yielding 4–50 ng/ml peak brain concentrations and 2 µg/ml peak plasma concentrations from a 10mg/kg dose. These results indicate that our newly synthesized small molecule ABAD inhibitor have good drug properties with the ability to cross the blood brain barrier, which holds a great potential for AD therapy.en_US
dc.publisherIOS Pressen_US
dc.relation.isversionofhttp://content.iospress.com/articles/journal-of-alzheimers-disease/jad140252en_US
dc.rightsCopyright IOS Pressen_US
dc.subjectABAD inhibitorsen_US
dc.subjectAmyloid-βen_US
dc.subjectBenzothiazole phosphonatesen_US
dc.subjectBlood-brain barrier pharmacokineticsen_US
dc.titleDetermination of Small Molecule ABAD Inhibitors Crossing Blood Brain Barrier and Pharmacokineticsen_US
dc.typeArticleen_US
kusw.kuauthorYan, Shirley ShiDu
kusw.kudepartmentPharmacology & Toxicologyen_US
dc.identifier.doi10.3233/JAD-140252en_US
kusw.oaversionScholarly/refereed, author accepted manuscripten_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record